Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Generic Drugs
Sales of biologics to drop 60 percent by 2015 as biogeneric competition becomes reality
September 20th, 2006
Decision Resources finds that the U.S. and European markets for branded biologics in the four key biologic classes (ESPs, G-CSF, insulin and insulin analogues, and hGH) will decline through 2015 as biogenerics gradually become available. In the United States, a major turning point will occur in 2013 as biogeneric ESPs and G-CSF become available; the U.S. branded biologics market for these four classes will shrink from $8 billion in 2012 to less than $3.8 billion in 2015. In Europe, competition in these key classes has begun with the launch of the hGH biosimilar Omnitrope this year, and will continue with biogeneric launches in the other classes in 2007 and 2008. ...
Source: Biotech Week (2006-09-20)
|
